{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:22Z","timestamp":1793242342468,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ymgme.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T04:21:39Z","timestamp":1547785299000},"page":"271-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Porphyria cutanea tarda: Recent update"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-7285","authenticated-orcid":false,"given":"Ashwani K.","family":"Singal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ymgme.2019.01.004_bb0005","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1093\/emboj\/cdg606","article-title":"Structural basis for tetrapyrrole coordination by uroporphyrinogen decarboxylase","volume":"22","author":"Phillips","year":"2003","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.ymgme.2019.01.004_bb0010","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1073\/pnas.0700547104","article-title":"A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda","volume":"104","author":"Phillips","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0015","first-page":"613","article-title":"Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria","volume":"36","author":"de Verneuil","year":"1984","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2019.01.004_bb0020","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1021\/ac702244x","article-title":"Direct assay of enzymes in heme biosynthesis for the detection of porphyrias by tandem mass spectrometry","volume":"80","author":"Wang","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0025","first-page":"88","article-title":"Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide","volume":"183","author":"Can","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2019.01.004_bb0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ajim.4700250410","article-title":"Evaluation of porphyria cutanea tarda in U.S. workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin","author":"Calvert","year":"1994","journal-title":"Am. J. Ind. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2340\/00015555-0472","article-title":"Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study","volume":"88","author":"Dereure","year":"2008","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0040","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1046\/j.1365-2133.2000.03874.x","article-title":"Iron overload in porphyria cutanea tarda","volume":"143","author":"Bygum","year":"2000","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0741-8329(03)00127-7","article-title":"Iron as a co-morbid factor in nonhemochromatotic liver disease","volume":"30","author":"Bonkovsky","year":"2003","journal-title":"Alcohol"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.0954-6820.1970.tb08003.x","article-title":"Iron storage in porphyria cutanea tarda","volume":"1\u20132","author":"Lundvall","year":"1970","journal-title":"Acta Med. Scand."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0055","first-page":"227","article-title":"Porphyrin metabolism in porphyria cutanea tarda","volume":"14","author":"Elder","year":"1977","journal-title":"Semin. Hematol."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0060","first-page":"248","article-title":"Iron overload in porphyria cutanea tarda","volume":"84","author":"Sampietro","year":"1999","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0041-008X(81)90009-0","article-title":"The role of iron in the toxicity of 2,3,7,8-tetrachlorodibenzo-(p)-dioxin (TCDD)","volume":"61","author":"Jones","year":"1981","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0070","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/hep.510270627","article-title":"Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America","volume":"27","author":"Bonkovsky","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0075","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.22486","article-title":"Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity","volume":"48","author":"Miura","year":"2008","journal-title":"Hepatology"},{"issue":"166","key":"10.1016\/j.ymgme.2019.01.004_bb0080","first-page":"341","article-title":"Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria","volume":"42","author":"Turnbull","year":"1973","journal-title":"Q. J. Med."},{"issue":"12","key":"10.1016\/j.ymgme.2019.01.004_bb0085","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood-2008-02-138222","article-title":"Down-regulation of hepcidin in porphyria cutanea tarda","volume":"112","author":"Ajioka","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0090","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1111\/j.1468-3083.2012.04511.x","article-title":"Increased serum hepcidin levels in patients with porphyria cutanea tarda","volume":"27","author":"Darwich","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2340\/00015555-0853","article-title":"Hemojuvelin and hepcidin gene mutations in patients with porphyria cutanea tarda from Southern France","volume":"91","author":"Du Thanh","year":"2011","journal-title":"Acta Derm. Venereol."},{"issue":"169","key":"10.1016\/j.ymgme.2019.01.004_bb0100","first-page":"1","article-title":"The treatment of porphyria cutanea tarda by venesection","volume":"43","author":"Ramsay","year":"1974","journal-title":"Q. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-0960.1988.tb01216.x","article-title":"Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection","volume":"29","author":"Ratnaike","year":"1988","journal-title":"Australas. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0110","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hep.510270237","article-title":"Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection","volume":"27","author":"Moran","year":"1998","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ymgme.2019.01.004_bb0115","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V98.12.3179","article-title":"Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase","volume":"98","author":"Phillips","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.11.017","article-title":"Associations among behavior-related susceptibility factors in porphyria cutanea tarda","volume":"8","author":"Jalil","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1013746828074","article-title":"Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency","volume":"47","author":"Egger","year":"2002","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2019.01.004_bb0130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","article-title":"Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda","volume":"10","author":"Singal","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"247","key":"10.1016\/j.ymgme.2019.01.004_bb0135","first-page":"953","article-title":"Long-term effect of high-dose, short-course chloroquine therapy on porphyria cutanea tarda","volume":"65","author":"Tsega","year":"1987","journal-title":"Q. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1346-8138.1994.tb01764.x","article-title":"Relationship between porphyria cutanea tarda (PCT) and viral hepatitis","volume":"21","author":"Tsukazaki","year":"1994","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0145","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hep.510260139","article-title":"High prevalence of hepatitis C virus infection in Japanese patients with porphyria cutanea tarda","volume":"26","author":"Kondo","year":"1997","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0168-8278(98)80313-9","article-title":"The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients","volume":"28","author":"Stuart","year":"1998","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0155","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.0954-6820.1963.tb17431.x","article-title":"Follow-up studies on an unselected ten-year material of 360 patients with liver cirrhosis in one community","volume":"173","author":"Hallen","year":"1963","journal-title":"Acta Med. Scand."},{"issue":"1 Suppl","key":"10.1016\/j.ymgme.2019.01.004_bb0160","first-page":"S2","article-title":"Hepcidin is down-regulated in alcohol loading","volume":"31","author":"Ohtake","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"10","key":"10.1016\/j.ymgme.2019.01.004_bb0165","first-page":"1019","article-title":"Uroporphyrinogen oxidation catalyzed by human cytochromes P450","volume":"26","author":"Sinclair","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0170","first-page":"1","article-title":"Hepatitis C virus infection was not found in patients with sporadic porphyria cutanea tarda, membranoproliferative glomerulonephritis or membranous glomerulonephritis in Northern Norway","author":"Kristiansen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0175","series-title":"J. Porphyria Cutanea Tarda","author":"Singal","year":"2014"},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MD.0b013e3181d50928","article-title":"Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients","volume":"89","author":"Munoz-Santos","year":"2010","journal-title":"Medicine"},{"issue":"4 Suppl 2","key":"10.1016\/j.ymgme.2019.01.004_bb0185","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1097\/01.mcg.0000155517.02468.46","article-title":"Mitochondrial dysfunction in hepatitis C","volume":"39","author":"Korenaga","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0190","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.V95.5.1565.005k42_1565_1571","article-title":"Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda","volume":"95","author":"Bulaj","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2133.2008.08693.x","article-title":"High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic","volume":"159","author":"Kratka","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.ymgme.2019.01.004_bb0200","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/j.1572-0241.2000.03369.x","article-title":"Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection","volume":"95","author":"Martinelli","year":"2000","journal-title":"Am. J. Gastroenterol."},{"issue":"9048","key":"10.1016\/j.ymgme.2019.01.004_bb0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(96)09436-6","article-title":"Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda","volume":"349","author":"Roberts","year":"1997","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ymgme.2019.01.004_bb0210","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJM199705013361817","article-title":"Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda","volume":"336","author":"Santos","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0215","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.510300626","article-title":"C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria","volume":"30","author":"Ivanova","year":"1999","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.ymgme.2019.01.004_bb0220","first-page":"728","article-title":"Significance and prevalence of the C282Y gene mutation of primary hemochromatosis in the pathogenesis of pophyria cutanea tarda","volume":"139","author":"Malina","year":"2000","journal-title":"Cas. Lek. Cesk."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hep.510270128","article-title":"High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda","volume":"27","author":"Sampietro","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0230","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1523-1747.1998.00400.x","article-title":"Are His63Asp or Cys282Tyr HFE mutations associated with porphyria cutanea tarda? Data of patients from central and southern Italy","volume":"111","author":"D'Amato","year":"1998","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0235","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/hep.510300627","article-title":"Extremely rare association of HFE mutations with porphyria cutanea tarda in Japanese patients","volume":"30","author":"Furuyama","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0240","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1098-1004(1999)14:3<222::AID-HUMU5>3.0.CO;2-V","article-title":"Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis. Identification and characterization of six novel mutations associated with familial PCT","volume":"14","author":"Christiansen","year":"1999","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0245","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/hep.21885","article-title":"Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls","volume":"46","author":"Ellervik","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0250","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.2830250112","article-title":"Porphyria cutanea tarda associated with the acquired immune deficiency syndrome","volume":"25","author":"Wissel","year":"1987","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.ymgme.2019.01.004_bb0255","first-page":"492","article-title":"Porphyria cutanea tarda associated with human immunodeficiency virus infection","volume":"8","author":"Drobacheff","year":"1998","journal-title":"Eur. J. Dermatol."},{"issue":"8","key":"10.1016\/j.ymgme.2019.01.004_bb0260","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/archderm.1996.03890320054009","article-title":"Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection","volume":"132","author":"Nomura","year":"1996","journal-title":"Arch. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/phpp.12222","article-title":"Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital","volume":"32","author":"Aguilera","year":"2016","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0270","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archderm.1970.04000090022004","article-title":"Estrogen-induced porphyria cutanea tarda. Report of three cases","volume":"102","author":"Roenigk","year":"1970","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archderm.1965.01600150042007","article-title":"Porphyria cutanea tarda induced by estrogens","volume":"92","author":"Becker","year":"1965","journal-title":"Arch. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0280","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1385\/MO:19:2:121","article-title":"Tamoxifen-related porphyria cutanea tarda","volume":"19","author":"Agarwal","year":"2002","journal-title":"Med. Oncol."},{"issue":"9","key":"10.1016\/j.ymgme.2019.01.004_bb0285","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D38XM7N81B","article-title":"Porphyria cutanea tarda induced by tamoxifen","volume":"16","author":"Cruz","year":"2010","journal-title":"Dermatol. Online J."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0290","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1067\/mlc.2000.111024","article-title":"Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda","volume":"136","author":"Bulaj","year":"2000","journal-title":"J. Lab. Clin. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0295","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0190-9622(98)70119-7","article-title":"Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients","volume":"38","author":"Gibson","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/1523-1747.ep12276482","article-title":"A porphyria cutanea tarda-like distribution pattern of porphyrins in plasma, hemodialysate, hemofiltrate, and urine of patients on chronic hemodialysis","volume":"85","author":"Seubert","year":"1985","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0305","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0002-9343(79)90403-0","article-title":"Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients","volume":"67","author":"Grossman","year":"1979","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0310","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0781.1997.tb00218.x","article-title":"Porphyria cutanea tarda and hematologic malignancy\u2014a report of 4 cases","volume":"13","author":"McKenna","year":"1997","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0315","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcmd.2011.07.006","article-title":"Uroporphyria in the Cyp1a2\u2212\/\u2212 mouse","volume":"47","author":"Phillips","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0320","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s004390000415","article-title":"Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda","volume":"107","author":"Christiansen","year":"2000","journal-title":"Hum. Genet."},{"issue":"8","key":"10.1016\/j.ymgme.2019.01.004_bb0325","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1111\/j.1600-0625.2009.01040.x","article-title":"Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda","volume":"19","author":"Fontanellas","year":"2010","journal-title":"Exp. Dermatol."},{"issue":"3\u20134","key":"10.1016\/j.ymgme.2019.01.004_bb0330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2119\/molmed.2010.00130","article-title":"CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda","volume":"17","author":"Wickliffe","year":"2011","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0335","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/00015550410025219","article-title":"No significant association between CYP1A2 polymorphism and porphyria cutanea tarda","volume":"84","author":"Dereure","year":"2004","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0340","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2133.2011.10642.x","article-title":"Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda","volume":"166","author":"Tchernitchko","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0345","series-title":"Sn Diego Elsevier Science","article-title":"Porphyria cutanea tarda and related disorders","author":"GH","year":"2003"},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0350","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ymgme.2012.02.002","article-title":"Molecular analysis of the UROD gene in 17 Argentinean patients with familial porphyria cutanea tarda: Characterization of four novel mutations","volume":"105","author":"Mendez","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0360","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0308-2261(21)00178-8","article-title":"Cutaneous porphyria","volume":"9","author":"Magnus","year":"1980","journal-title":"Clin. Haematol."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0365","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1172\/JCI111616","article-title":"Activation of the complement system in patients with porphyrias after irradiation in vivo","volume":"74","author":"Lim","year":"1984","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0370","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0560.1992.tb01557.x","article-title":"Histologic and immunofluorescence study of cutaneous porphyrias","volume":"19","author":"Maynard","year":"1992","journal-title":"J. Cutan. Pathol."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0375","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/1523-1747.ep12676478","article-title":"The molecular basis of the action of chloroquine in porphyria cutanea tarda","volume":"61","author":"Scholnick","year":"1973","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0380","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2133.1993.tb03176.x","article-title":"Generalized morphoea secondary to porphyria cutanea tarda","volume":"129","author":"Stevens","year":"1993","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.ymgme.2019.01.004_bb0385","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1346-8138.1995.tb03930.x","article-title":"The porphyrias: a brief overview based on 25 years of experience (1969-1994) by the Department of Dermatology of the Hospital Clinic and Faculty of Medicine of Barcelona, Spain","volume":"22","author":"Mascaro","year":"1995","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0390","series-title":"Kadish KM SK","first-page":"67","article-title":"Porphyria cutanea tarda and related disorders","author":"Elder","year":"2003"},{"key":"10.1016\/j.ymgme.2019.01.004_bb0395","series-title":"Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemias and the Porphyrias","first-page":"2991","author":"Anderson","year":"2001"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1172\/JCI110423","article-title":"Uroporphyrin I stimulation of collagen biosynthesis in human skin fibroblasts. A unique dark effect of porphyrin","volume":"69","author":"Varigos","year":"1982","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.ymgme.2019.01.004_bb0405","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/ICO.0b013e31817e905a","article-title":"Ocular complications in 2 cases with porphyria","volume":"27","author":"Altiparmak","year":"2008","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2559.1980.tb02942.x","article-title":"The pathology of the liver in porphyria cutanea tarda","volume":"4","author":"Cortes","year":"1980","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0415","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.1980.tb08138.x","article-title":"Liver changes in porphyria cutanea tarda patients treated with chloroquine","volume":"102","author":"Chlumska","year":"1980","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0420","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/0016-5085(83)90369-4","article-title":"Serum antibodies against porphyric hepatocytes in patients with porphyria cutanea tarda and liver disease","volume":"84","author":"Baravalle","year":"1983","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0425","first-page":"135","article-title":"Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long-term follow-up","volume":"19","author":"Kordac","year":"1972","journal-title":"Neoplasma"},{"issue":"11","key":"10.1016\/j.ymgme.2019.01.004_bb0430","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/oxfordjournals.aje.a009745","article-title":"Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden","volume":"149","author":"Linet","year":"1999","journal-title":"Am. J. Epidemiol."},{"issue":"11","key":"10.1016\/j.ymgme.2019.01.004_bb0435","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/oxfordjournals.aje.a009745","article-title":"Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden","volume":"149","author":"Linet","year":"1999","journal-title":"Am. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0440","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0168-8278(01)00160-X","article-title":"Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease","volume":"35","author":"Fracanzani","year":"2001","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.ymgme.2019.01.004_bb0445","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/01.meg.0000108318.52416.c9","article-title":"Hepatocellular carcinoma risk in patients with porphyria cutanea tarda","volume":"16","author":"Gisbert","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0450","doi-asserted-by":"crossref","first-page":"S1156","DOI":"10.1016\/S0016-5085(17)33873-8","article-title":"Porphyria cutanea tarda: profile of 189 patients from the porphyrias consortium in the United States","volume":"152","author":"Singal","year":"2017","journal-title":"Gastroenetrology"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0455","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-2007-1007142","article-title":"Porphyria cutanea tarda","volume":"18","author":"Elder","year":"1998","journal-title":"Semin. Liver Dis."},{"issue":"5\u20136","key":"10.1016\/j.ymgme.2019.01.004_bb0460","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/0020-711X(80)90216-5","article-title":"The prophyrins of normal human urine, with a comparison of the excretion pattern in porphyria cutanea tarda","volume":"12","author":"Smith","year":"1980","journal-title":"Int. J. BioChemiPhysics"},{"issue":"Pt 1","key":"10.1016\/j.ymgme.2019.01.004_bb0465","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/000456306775141641","article-title":"Dual porphyria with mutations in both the UROD and HMBS genes","volume":"43","author":"Harraway","year":"2006","journal-title":"Ann. Clin. Biochem."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0470","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0022-3476(05)80887-X","article-title":"Pseudoporphyria versus porphyria cutanea tarda","volume":"123","author":"Anderson","year":"1993","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0475","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2133.1984.tb04019.x","article-title":"Recovery from porphyria cutanea tarda with no specific therapy other than avoidance of hepatic toxins","volume":"111","author":"Topi","year":"1984","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.ymgme.2019.01.004_bb0480","first-page":"653","article-title":"Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens","volume":"113","author":"Haberman","year":"1975","journal-title":"Can. Med. Assoc. J."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0485","first-page":"43","article-title":"Treatment of porphyria cutanea tarda with and without phlebotomy (author's transl)","volume":"119","author":"Leonhardi","year":"1977","journal-title":"MMW Munch Med. Wochenschr."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0490","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0028-1112755","article-title":"General symptoms of late skin porphyria (porphyria cutanea tarda) as an indication for its treatment","volume":"86","author":"Ippen","year":"1961","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"24","key":"10.1016\/j.ymgme.2019.01.004_bb0495","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM196812122792402","article-title":"Porphyria cutanea tarda. A study of the effect of phlebotomy","volume":"279","author":"Epstein","year":"1968","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2019.01.004_bb0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.0954-6820.1971.tb04337.x","article-title":"The effect of phlebotomy therapy in porphyria cutanea tarda. Its relation to the phlebotomy-induced reduction of iron stores","volume":"189","author":"Lundvall","year":"1971","journal-title":"Acta Med. Scand."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0505","first-page":"124","article-title":"The effect of venesection therapy on liver tissue in porphyria cutanea tarda","volume":"20","author":"Chlumsky","year":"1973","journal-title":"Acta Hepatogastroenterol. (Stuttg.)"},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0510","first-page":"253","article-title":"Treatment of porphyria cutanea tarda by phlebotomy","volume":"14","author":"Ippen","year":"1977","journal-title":"Semin. Hematol."},{"issue":"5\u20136","key":"10.1016\/j.ymgme.2019.01.004_bb0515","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0020-711X(80)90175-5","article-title":"Patterns of porphyrin excretion in porphyria cutanea tarda under venesection treatment","volume":"12","author":"Enriquez de Salamanca","year":"1980","journal-title":"Int. J. BioChemiPhysics"},{"key":"10.1016\/j.ymgme.2019.01.004_bb0520","first-page":"107","article-title":"Phlebotomy treatment of porphyria cutanea tarda","volume":"100","author":"Lundvall","year":"1982","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0525","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00000441-198301000-00001","article-title":"Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda","volume":"285","author":"Di Padova","year":"1983","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0530","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000249600","article-title":"Phlebotomy treatment in porphyria cutanea tarda combined with beta-thalassaemia","volume":"169","author":"Adjarov","year":"1984","journal-title":"Dermatologica"},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0535","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2133.1986.tb04071.x","article-title":"Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion","volume":"114","author":"Rocchi","year":"1986","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0540","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/jcp.25.4.326","article-title":"An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload","volume":"25","author":"Addison","year":"1972","journal-title":"J. Clin. Pathol."},{"issue":"10","key":"10.1016\/j.ymgme.2019.01.004_bb0545","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/jcp.26.10.770","article-title":"Serum ferritin concentration and iron stores in normal subjects","volume":"26","author":"Walters","year":"1973","journal-title":"J. Clin. Pathol."},{"issue":"7","key":"10.1016\/j.ymgme.2019.01.004_bb0550","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ajcn\/27.7.681","article-title":"Serum ferritin as a measure of iron stores in normal subjects","volume":"27","author":"Cook","year":"1974","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0555","first-page":"36","article-title":"Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda","volume":"107","author":"Rocchi","year":"1986","journal-title":"J. Lab. Clin. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0560","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00005792-196645060-00024","article-title":"Effect of chloroquine on hepatic uroporphyrin metabolism in patients with porphyria cutanea tarda","volume":"45","author":"Felsher","year":"1966","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0565","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0002-9343(70)80022-5","article-title":"Biochemical effects of chloroquine therapy in porphyria cutanea tarda","volume":"49","author":"Vogler","year":"1970","journal-title":"Am. J. Med."},{"issue":"5445","key":"10.1016\/j.ymgme.2019.01.004_bb0570","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/bmj.1.5445.1281","article-title":"Effects of chloroquine on patients with cutaneous porphyria of the \"Symptomatic\" type","volume":"1","author":"Sweeney","year":"1965","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0575","first-page":"119","article-title":"Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy","volume":"100","author":"Wennersten","year":"1982","journal-title":"Acta Derm. Venereol. Suppl. (Stockh)"},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0580","first-page":"456","article-title":"Treatment of porphyria cutanea tarda with chloroquine and its effect on associated liver disease: retrospective analysis","volume":"124","author":"Wolff","year":"1996","journal-title":"Rev. Med. Chil."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0585","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.1984.tb06632.x","article-title":"Low-dose oral chloroquine in the treatment of porphyria cutanea tarda","volume":"111","author":"Ashton","year":"1984","journal-title":"Br. J. Dermatol."},{"issue":"16","key":"10.1016\/j.ymgme.2019.01.004_bb0590","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM197704212961627","article-title":"Chloroquine in the treatment of porphyria cutanea tarda","volume":"296","author":"Kordac","year":"1977","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0595","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000211340","article-title":"Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver","volume":"8","author":"Freesemann","year":"1995","journal-title":"Skin Pharmacol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0600","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF00414107","article-title":"Influence of chloroquine on the porphyrin metabolism","volume":"277","author":"Goerz","year":"1985","journal-title":"Arch. Dermatol. Res."},{"issue":"40","key":"10.1016\/j.ymgme.2019.01.004_bb0605","first-page":"1225","article-title":"Chloroquine in the treatment of porphyria cutanea tarda symptomatica. Twelve years of experience in 307 patients (author's transl)","volume":"120","author":"Kordac","year":"1981","journal-title":"Cas. Lek. Cesk."},{"issue":"5 Pt 2","key":"10.1016\/j.ymgme.2019.01.004_bb0610","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0190-9622(98)70464-5","article-title":"Childhood-onset porphyria cutanea tarda: successful therapy with low-dose hydroxychloroquine (Plaquenil)","volume":"38","author":"Bruce","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0615","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archderm.139.3.309","article-title":"Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda","volume":"139","author":"Stolzel","year":"2003","journal-title":"Arch. Dermatol."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0620","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00561503","article-title":"Letter: Porphyria cutanea tarda: normalization of porphyrin-excretion following treatment with p-amino-benzoic acid (Potaba) (author's transl)","volume":"255","author":"Goerz","year":"1976","journal-title":"Arch. Dermatol. Res."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0625","first-page":"286","article-title":"A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients","volume":"1","author":"Marchesi","year":"1984","journal-title":"Photo-Dermatology"},{"issue":"12","key":"10.1016\/j.ymgme.2019.01.004_bb0630","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1158\/1078-0432.CCR-13-3227","article-title":"Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer","volume":"20","author":"Cook","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0635","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.1983.tb01062.x","article-title":"Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda","volume":"108","author":"Cainelli","year":"1983","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0640","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.1983.tb01062.x","article-title":"Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda","volume":"108","author":"Cainelli","year":"1983","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0645","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(25)12474-9","article-title":"Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues","volume":"253","author":"De Waziers","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0650","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000247732","article-title":"Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda","volume":"182","author":"Rocchi","year":"1991","journal-title":"Dermatologica"},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0655","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dth.12024","article-title":"Desferrioxamine treatment of porphyria cutanea tarda in a patient with HIV and chronic renal failure","volume":"27","author":"Vasconcelos","year":"2014","journal-title":"Dermatol. Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0660","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1346-8138.1990.tb01651.x","article-title":"Desferrioxamine in the treatment of porphyria cutanea tarda: ineffectiveness of intramuscular administration","volume":"17","author":"Munoz","year":"1990","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0665","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJM199002013220507","article-title":"Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis","volume":"322","author":"Anderson","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2019.01.004_bb0670","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archderm.1983.01650330044012","article-title":"Small volume plasmapheresis in the management of porphyria cutanea tarda","volume":"119","author":"Miyauchi","year":"1983","journal-title":"Arch. Dermatol."},{"issue":"1","key":"10.1016\/j.ymgme.2019.01.004_bb0675","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10545-010-9231-2","article-title":"Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study","volume":"34","author":"Tollanes","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0680","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2340\/0001555564444445","article-title":"Pregnancy and porphyria cutanea tarda","volume":"64","author":"Rajka","year":"1984","journal-title":"Acta Derm. Venereol."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0685","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.ymgme.2019.01.004_bb0690","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.reprotox.2013.04.005","article-title":"Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study","volume":"39","author":"Diav-Citrin","year":"2013","journal-title":"Reprod. Toxicol."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0695","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/00365520310000672a","article-title":"Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C","volume":"38","author":"Fernandez","year":"2003","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2019.01.004_bb0700","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/bjd.15502","article-title":"Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda","volume":"177","author":"Combalia","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2019.01.004_bb0705","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cgh.2006.06.010","article-title":"Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy","volume":"5","author":"Berk","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.ymgme.2019.01.004_bb0710","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjms.2017.03.007","article-title":"Hepatitis C treatment in patients with porphyria cutanea tarda","volume":"353","author":"Singal","year":"2017","journal-title":"Am J Med Sci"},{"issue":"10","key":"10.1016\/j.ymgme.2019.01.004_bb0715","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archderm.1980.01640340057016","article-title":"Hydroxychloroquine treatment of porphyria cutanea tarda","volume":"116","author":"Malkinson","year":"1980","journal-title":"Arch. Dermatol."},{"issue":"4","key":"10.1016\/j.ymgme.2019.01.004_bb0720","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/0190-9622(92)70090-3","article-title":"High-dose hydroxychloroquine treatment of porphyria cutanea tarda","volume":"26","author":"Petersen","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.ymgme.2019.01.004_bb0725","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2340\/00015555-0260","article-title":"Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment","volume":"87","author":"Rossmann-Ringdahl","year":"2007","journal-title":"Acta Derm. Venereol."},{"issue":"3","key":"10.1016\/j.ymgme.2019.01.004_bb0730","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0923-1811(94)90092-2","article-title":"Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload","volume":"7","author":"Valls","year":"1994","journal-title":"J. Dermatol. Sci."},{"issue":"11","key":"10.1016\/j.ymgme.2019.01.004_bb0735","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1365-4632.2009.04205.x","article-title":"Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?","volume":"48","author":"Wollina","year":"2009","journal-title":"Int. J. Dermatol."},{"issue":"Supplement","key":"10.1016\/j.ymgme.2019.01.004_bb0740","article-title":"Relapse of porphyria cutanea tarda after achieving remission with phlebotomy or low dose hydroxychloroquine","volume":"62","author":"Singal","year":"2015","journal-title":"Hepatology"},{"issue":"Supplement","key":"10.1016\/j.ymgme.2019.01.004_bb0745","first-page":"1238A","article-title":"Relapse of porphyria cutanea tarda after achieving remission: a meta-analysis","volume":"62","author":"Rizwan","year":"2015","journal-title":"Hepatology"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218305791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218305791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:24:23Z","timestamp":1761089063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218305791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1096719218305791"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Porphyria cutanea tarda: Recent update","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}